中国苏州，4月25日，韩国生物制药上市企业Genexine (KOSDAQ: 095700)与中国创新药企星锐医药正式达成战略合作，双方将依托前沿的肺靶向LNP递送技术，共同开拓肺部疾病治疗新领域。

Suzhou, China, April 25th, 2025, Korean biopharmaceutical company Genexine and China-based innovative drug developer Starna Therapeutics officially entered into a strategic collaboration. Leveraging cutting-edge lung-targeted LNP delivery technology, the two companies will jointly explore new frontiers in pulmonary disease treatment.

此次合作的核心是星锐医药自主研发的STAR LNP递送技术平台。该平台突破了传统LNP体系易在肝脏富集的技术瓶颈，能够实现核酸药物向肺脏的高效精准递送，为肺部疾病的靶向治疗提供了全新的技术路径。基于这一创新技术平台，双方将联合开展临床前候选分子的筛选验证及CMC生产，并共同推动相关项目进入临床开发阶段。

At the core of this partnership is Starna’s proprietary STAR-LNP delivery platform, which overcomes the technical limitations of traditional LNP systems that tend to accumulate in the liver. Instead, it enables highly efficient and precise delivery of nucleic acid drugs to the lungs, offering a novel technological approach for targeted pulmonary disease therapies. Based on this innovative platform, the two parties will collaborate on preclinical candidate screening and validation, CMC production, and jointly advance projects into clinical development.